Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: Clin Cancer Res. 2021 Jan 7;27(6):1695–1705. doi: 10.1158/1078-0432.CCR-20-4073

Figure 4.

Figure 4

A. Radiographic trajectory of patient with ROS1-GOPC fusion showing consistent growth in retrocrural (A) and left internal iliac lymph nodes (B) between April and December 2019 whilst the patient was being closely observed. Entrectinib was initiated in early January 2020. Scans 8 months into therapy in August 2020 show stable disease with slight reduction in size of adenopathy. Measurements of index retrocrural nodes used for RECIST1.1 measurements are noted. The left internal iliac node is too small for measurements but was FDG avid on a prior PET CT.